On Monday, Context Therapeutics Inc (NASDAQ: CNTX) opened higher 7.08% from the last session, before settling in for the closing price of $1.13. Price fluctuations for CNTX have ranged from $0.49 to $1.55 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 4.72%. Company’s average yearly earnings per share was noted 24.15% at the time writing. With a float of $61.00 million, this company’s outstanding shares have now reached $91.88 million.
Context Therapeutics Inc (CNTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Context Therapeutics Inc is 33.61%, while institutional ownership is 43.09%. The most recent insider transaction that took place on Jun 09 ’25, was worth 70,080. In this transaction Chief Executive Officer of this company bought 100,000 shares at a rate of $0.70, taking the stock ownership to the 920,190 shares. Before that another transaction happened on Jun 06 ’25, when Company’s Chief Legal Officer, Corp. Sec bought 20,000 for $0.58, making the entire transaction worth $11,520. This insider now owns 29,000 shares in total.
Context Therapeutics Inc (CNTX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 0 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.09) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.76% during the next five years compared to 4.72% growth over the previous five years of trading.
Context Therapeutics Inc (NASDAQ: CNTX) Trading Performance Indicators
Check out the current performance indicators for Context Therapeutics Inc (CNTX). In the past quarter, the stock posted a quick ratio of 13.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Context Therapeutics Inc (CNTX)
Looking closely at Context Therapeutics Inc (NASDAQ: CNTX), its last 5-days average volume was 0.42 million, which is a jump from its year-to-date volume of 0.27 million. As of the previous 9 days, the stock’s Stochastic %D was 40.62%.
During the past 100 days, Context Therapeutics Inc’s (CNTX) raw stochastic average was set at 61.12%, which indicates a significant decrease from 61.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1006 in the past 14 days, which was higher than the 0.0886 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1452, while its 200-day Moving Average is $0.8879. However, in the short run, Context Therapeutics Inc’s stock first resistance to watch stands at $1.2633. Second resistance stands at $1.3167. The third major resistance level sits at $1.4033. If the price goes on to break the first support level at $1.1233, it is likely to go to the next support level at $1.0367. Now, if the price goes above the second support level, the third support stands at $0.9833.
Context Therapeutics Inc (NASDAQ: CNTX) Key Stats
There are currently 91,879K shares outstanding in the company with a market cap of 111.17 million. Presently, the company’s annual sales total 0 K according to its annual income of -26,730 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -9,690 K.
